Chicago Capital LLC Decreases Stake in AstraZeneca PLC (NASDAQ:AZN)

Chicago Capital LLC lessened its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 26.1% in the 4th quarter, Holdings Channel reports. The fund owned 4,292 shares of the company’s stock after selling 1,514 shares during the quarter. Chicago Capital LLC’s holdings in AstraZeneca were worth $281,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of AZN. FSM Wealth Advisors LLC raised its stake in AstraZeneca by 3.3% during the fourth quarter. FSM Wealth Advisors LLC now owns 6,342 shares of the company’s stock worth $424,000 after purchasing an additional 204 shares during the period. HHM Wealth Advisors LLC increased its holdings in shares of AstraZeneca by 38.8% during the 4th quarter. HHM Wealth Advisors LLC now owns 1,163 shares of the company’s stock worth $76,000 after buying an additional 325 shares during the last quarter. Stock Yards Bank & Trust Co. raised its position in shares of AstraZeneca by 17.8% during the 4th quarter. Stock Yards Bank & Trust Co. now owns 8,116 shares of the company’s stock valued at $532,000 after buying an additional 1,224 shares during the period. Valley National Advisers Inc. lifted its holdings in AstraZeneca by 2.2% in the fourth quarter. Valley National Advisers Inc. now owns 23,470 shares of the company’s stock valued at $1,537,000 after acquiring an additional 508 shares during the last quarter. Finally, U.S. Capital Wealth Advisors LLC grew its position in AstraZeneca by 25.7% in the fourth quarter. U.S. Capital Wealth Advisors LLC now owns 4,933 shares of the company’s stock worth $323,000 after acquiring an additional 1,008 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Price Performance

AZN stock opened at $69.86 on Tuesday. The business’s fifty day moving average price is $67.08 and its 200 day moving average price is $73.85. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $216.64 billion, a PE ratio of 33.43, a P/E/G ratio of 1.18 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. During the same period in the prior year, the firm earned $0.87 earnings per share. The business’s revenue for the quarter was up 18.0% compared to the same quarter last year. On average, sell-side analysts anticipate that AstraZeneca PLC will post 4.13 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on AZN shares. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.